Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA     Guest: Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA  The National Lipid Association (NLA) recently published updated recommendations for lifestyle therapies to manage three common dyslipidemias in adults. To discuss this, Dr. Mary Katherine Cheeley is joined by Dr. Carol Kirkpatrick, Clinical Lipid Specialist and Clinical Scientist at Midwest Biomedical Research.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA The National Lipid Association (NLA) recently published updated recommendations for lifestyle therapies to manage three common dyslipidemias in adults. To discuss this, Dr. Mary Katherine Cheeley is joined by Dr. Carol Kirkpatrick, Clinical Lipid Specialist and Clinical Scientist at Midwest Biomedical Research.

A Discussion on the Updated Recommendations for Managing Dyslipidemia in Adults


Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA     Guest: Steve Grinspoon, MD  Many studies over the last few years have shown that the risks of cardiovascular disease have increased between 50 to 100 percent among patients with HIV. So what steps need to be taken to help reduce this risk for our patients? Here to discuss what we need to know is Dr. Mary Katherine Cheeley and Dr. Steven Grinspoon, Professor of Medicine at Harvard Medical School and Chief of the Metabolism Unit at Massachusetts General Hospital.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Steve Grinspoon, MD Many studies over the last few years have shown that the risks of cardiovascular disease have increased between 50 to 100 percent among patients with HIV. So what steps need to be taken to help reduce this risk for our patients? Here to discuss what we need to know is Dr. Mary Katherine Cheeley and Dr. Steven Grinspoon, Professor of Medicine at Harvard Medical School and Chief of the Metabolism Unit at Massachusetts General Hospital.

Identifying Cardiovascular Risk Factors for HIV Patients


Host: Alan S. Brown, MD, FACC, FAHA, FNLA     Guest: Maya S. Safarova, MD, PhD, FNLA  Learn which patients with low-density lipoprotein (LDL) would benefit from this group of medication. In this episode, Dr. Alan Brown is joined by Dr. Maya Safarova, Chief Fellow in the Department of Cardiovascular Medicine at the University of Kansas Medical Center, to discuss the benefits of non-statin LDL lowering therapies. 

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Maya S. Safarova, MD, PhD, FNLA Learn which patients with low-density lipoprotein (LDL) would benefit from this group of medication. In this episode, Dr. Alan Brown is joined by Dr. Maya Safarova, Chief Fellow in the Department of Cardiovascular Medicine at the University of Kansas Medical Center, to discuss the benefits of non-statin LDL lowering therapies.

Exploring Emerging Non-Statin LDL Lowering Therapies


Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA     Guest: Alan S. Brown, MD, FACC, FAHA, FNLA  Both clinical trials for lowering Lp(a) had patients with established atherosclerotic cardiovascular disease (ASCVD). Join in for a further discussion on important updates presented at the 2023 National Lipid Association Meeting with Dr. Mary Katherine Cheeley and fellow ReachMD host, Dr. Alan Brown, Past President of the National Lipid Association.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Alan S. Brown, MD, FACC, FAHA, FNLA Both clinical trials for lowering Lp(a) had patients with established atherosclerotic cardiovascular disease (ASCVD). Join in for a further discussion on important updates presented at the 2023 National Lipid Association Meeting with Dr. Mary Katherine Cheeley and fellow ReachMD host, Dr. Alan Brown, Past President of the National Lipid Association.

Assessing the Effectiveness of Lp(a) Lowering Therapies in Clinical Trials


Elevated lipoprotein(a), or Lp(a), is the most common inherited dyslipidemia that can drive the atherosclerotic process. So at what age does Lp(a) impact a patient’s life? To find out more, tune into this episode sponsored by Novartis.   Sponsored by Novartis Pharmaceuticals Corporation.  6/23 278623

Elevated lipoprotein(a), or Lp(a), is the most common inherited dyslipidemia that can drive the atherosclerotic process. So at what age does Lp(a) impact a patient’s life? To find out more, tune into this episode sponsored by Novartis. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

The ASCVD Journey With Lp(a): An ApoB-Family Lipoprotein


It’s estimated that 20 percent of the world’s population has elevated Lp(a) greater than 50 milligrams per deciliter. Lp(a) is an independent, genetic, and causal risk factor for atherosclerotic cardiovascular diseases. For more insights, tune into this episode sponsored by Novartis.   Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

It’s estimated that 20 percent of the world’s population has elevated Lp(a) greater than 50 milligrams per deciliter. Lp(a) is an independent, genetic, and causal risk factor for atherosclerotic cardiovascular diseases. For more insights, tune into this episode sponsored by Novartis. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

Letters from the Heart: People Should Know About Lp(a)


Guest: Santica Marcovina, PhD, ScD  Lipoprotein(a), or Lp(a), is a unique apoB family lipoprotein that contains apo(a), which is a peculiar carbohydrate-rich protein covalently bound to an apoB lipoprotein. So are elevated Lp(a) levels a risk factor for atherosclerotic cardiovascular disease? Dive into this episode, sponsored by Novartis, to find out.  Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

Guest: Santica Marcovina, PhD, ScD Lipoprotein(a), or Lp(a), is a unique apoB family lipoprotein that contains apo(a), which is a peculiar carbohydrate-rich protein covalently bound to an apoB lipoprotein. So are elevated Lp(a) levels a risk factor for atherosclerotic cardiovascular disease? Dive into this episode, sponsored by Novartis, to find out. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623

Understanding Lp(a): Clinical Implications of an Underrecognized Genetic Dyslipidemia


Host: Javed Butler, MD, MBA, MPH     Guest: John W. MacArthur  With many barriers standing in the way of people in the United States who need a heart transplant, fewer than 10 percent of patients actually receive this life-saving surgery according to Stanford Medicine. Therefore, surgeons are working on different techniques to increase the pool of healthy donated hearts. To speak more about this, Dr. Javed Butler is joined by Dr. John MacArthur, Assistant Professor of Cardiothoracic Surgery at Stanford School of Medicine.

Host: Javed Butler, MD, MBA, MPH Guest: John W. MacArthur With many barriers standing in the way of people in the United States who need a heart transplant, fewer than 10 percent of patients actually receive this life-saving surgery according to Stanford Medicine. Therefore, surgeons are working on different techniques to increase the pool of healthy donated hearts. To speak more about this, Dr. Javed Butler is joined by Dr. John MacArthur, Assistant Professor of Cardiothoracic Surgery at Stanford School of Medicine.

Stanford Surgeons Perform First Beating-Heart Procedure


Host: Javed Butler, MD, MBA, MPH     Guest: Pedro A Villablanca Spinetto, MD  A complex condition known as tricuspid valve regurgitation may cause concern for patients as it typically doesn’t show signs or symptoms until the disease is severe. So what technologies and therapies do we have to look forward to? Join Dr. Javed Butler as he speaks with Dr. Pedro Villablanca, Structural Heart Interventional Cardiologist at Henry Ford Health. 

Host: Javed Butler, MD, MBA, MPH Guest: Pedro A Villablanca Spinetto, MD A complex condition known as tricuspid valve regurgitation may cause concern for patients as it typically doesn’t show signs or symptoms until the disease is severe. So what technologies and therapies do we have to look forward to? Join Dr. Javed Butler as he speaks with Dr. Pedro Villablanca, Structural Heart Interventional Cardiologist at Henry Ford Health.

Treating Tricuspid Valve Regurgitation With Novel Replacement Device


Guest: Patricia A. Pellikka, M.D.  Artificial intelligence (AI) has several applications in cardiology, such as echocardiography. Can machine learning and AI algorithms in echocardiology help clinicians better detect heart failure with preserved ejection fraction (HFpEF)? Dr. Patricia A. Pellikka, Director of the Ultrasound Research Center at the Mayo Clinic, shares data from ACC.23 and explores the potential of AI in detecting HFpEF.

Guest: Patricia A. Pellikka, M.D. Artificial intelligence (AI) has several applications in cardiology, such as echocardiography. Can machine learning and AI algorithms in echocardiology help clinicians better detect heart failure with preserved ejection fraction (HFpEF)? Dr. Patricia A. Pellikka, Director of the Ultrasound Research Center at the Mayo Clinic, shares data from ACC.23 and explores the potential of AI in detecting HFpEF.

Exploring the Use of AI to Detect HFpEF


Since cardiovascular disease is one of the leading causes of death in the U.S., cardiology physicians are continuously working to better understand this common disease and to help patients improve their heart health. And here to assist cardiology physicians in this mission is Heart Matters, a series dedicated to covering essential strategies and research efforts focusing on all types of heart problems, including coronary artery diseases, heart attacks, high cholesterol, high blood pressure, and more.So whether you’re looking for ways to improve heart health or catch up on the latest cardiology research, you never have to worry about missing a beat thanks to Heart Matters.

Since cardiovascular disease is one of the leading causes of death in the U.S., cardiology physicians are continuously working to better understand this common disease and to help patients improve their heart health. And here to assist cardiology physicians in this mission is Heart Matters, a series dedicated to covering essential strategies and research efforts focusing on all types of heart problems, including coronary artery diseases, heart attacks, high cholesterol, high blood pressure, and more. So whether you’re looking for ways to improve heart health or catch up on the latest cardiology research, you never have to worry about missing a beat thanks to Heart Matters.

Heart Matters

Guest: Sanjay Kaul, MD, MPH     Host: Janet Wright, MD  Atrial-fibrillation, or a-fib, affects nearly 2.5 million patients in the US, and is one of the more common forms of arrhythmia. The antiarrhythmic armamentarium has been expanded to include dronedarone, which was recently approved by the FDA for the treatment of a-fib. What's the efficacy and safety of dronedarone, compared to other antiarrhythmic agents, and how should you use it? Dr. Sanjay Kaul, director of the Vascular Physiology and Thrombosis Research Laboratory at the Burns and Allen Research Institute at Cedars-Sinai Medical Center in Los Angeles, describes the profile of patients who should be considered candidates for dronedarone therapy. Will dronedarone replace the current gold standard for treating a-fib, amiodarone, and if not, where does dronedarone fit into the management algorithm for a-fib? Dr. Janet Wright hosts.   Produced in Cooperation with

Guest: Sanjay Kaul, MD, MPH Host: Janet Wright, MD Atrial-fibrillation, or a-fib, affects nearly 2.5 million patients in the US, and is one of the more common forms of arrhythmia. The antiarrhythmic armamentarium has been expanded to include dronedarone, which was recently approved by the FDA for the treatment of a-fib. What's the efficacy and safety of dronedarone, compared to other antiarrhythmic agents, and how should you use it? Dr. Sanjay Kaul, director of the Vascular Physiology and Thrombosis Research Laboratory at the Burns and Allen Research Institute at Cedars-Sinai Medical Center in Los Angeles, describes the profile of patients who should be considered candidates for dronedarone therapy. Will dronedarone replace the current gold standard for treating a-fib, amiodarone, and if not, where does dronedarone fit into the management algorithm for a-fib? Dr. Janet Wright hosts. <h2>Produced in Cooperation with</h2>

Expanding the Anti-Arrhythmia Armamentarium: Where Does Dronedarone Fit In?


Host: Alfred Bove, MD     Guest: Leslie Miller, MD  Options for patients with advanced heart failure used to be limited to heart transplantation, but ventricular assist devices have rapidly evolved into viable treatment options for these patients. How is the newest generation of continuous-flow devices impacting the way we care for patients with advanced heart failure? Which patients are the best candidates for ventricular assist devices, or VADs, and are many patients with VADs now undergoing the procedure as destination therapy, rather than a bridge to transplant? Dr. Leslie Miller, professor and chief of the Integrated Cardiology Programs at Washington Hospital Center and Georgetown University Hospital and School of Medicine, as well as the Walters Chair in Cardiovascular Medicine at Georgetown University in Washington, DC, tells host Dr. Alfred Bove about the evolution of VADs from pulsatile pumps to continuous flow design, and the various applications for these technologies. Will these devices play a more significant role in the treatment of patients with advanced heart failure in years to come?  Produced in Cooperation with

Host: Alfred Bove, MD Guest: Leslie Miller, MD Options for patients with advanced heart failure used to be limited to heart transplantation, but ventricular assist devices have rapidly evolved into viable treatment options for these patients. How is the newest generation of continuous-flow devices impacting the way we care for patients with advanced heart failure? Which patients are the best candidates for ventricular assist devices, or VADs, and are many patients with VADs now undergoing the procedure as destination therapy, rather than a bridge to transplant? Dr. Leslie Miller, professor and chief of the Integrated Cardiology Programs at Washington Hospital Center and Georgetown University Hospital and School of Medicine, as well as the Walters Chair in Cardiovascular Medicine at Georgetown University in Washington, DC, tells host Dr. Alfred Bove about the evolution of VADs from pulsatile pumps to continuous flow design, and the various applications for these technologies. Will these devices play a more significant role in the treatment of patients with advanced heart failure in years to come? <h2>Produced in Cooperation with</h2>

The Rapid Evolution of Ventricular Assist Devices


Host: Janet Wright, MD     Guest: Rita Redberg, MD, MSc  It is increasingly recognized that symptoms of heart disease are different for men and women. But it appears we are often slower to recognize heart disease in women, resulting in important distinctions in early treatment and outcomes. What are these differences, and how can we, as providers, help narrow this gender gap? Host Dr. Janet Wright welcomes Dr. Rita Redberg, professor of clinical medicine at the University of California, San Francisco, School of Medicine (UCSF), and director of women's cardiovascular services at the UCSF National Center for Excellence in Women's Health, for an important conversation about where can we do a better job of encouraging women to be aware of cardiac concerns specific to women? Dr. Redberg also shares her approach to evaluating female patients with symptoms that are suggestive but not definitive.

Host: Janet Wright, MD Guest: Rita Redberg, MD, MSc It is increasingly recognized that symptoms of heart disease are different for men and women. But it appears we are often slower to recognize heart disease in women, resulting in important distinctions in early treatment and outcomes. What are these differences, and how can we, as providers, help narrow this gender gap? Host Dr. Janet Wright welcomes Dr. Rita Redberg, professor of clinical medicine at the University of California, San Francisco, School of Medicine (UCSF), and director of women's cardiovascular services at the UCSF National Center for Excellence in Women's Health, for an important conversation about where can we do a better job of encouraging women to be aware of cardiac concerns specific to women? Dr. Redberg also shares her approach to evaluating female patients with symptoms that are suggestive but not definitive.

Women and Heart Disease: Closing the Outcomes Gap


Host: Janet Wright, MD     Guest: Robert Harrington, MD  Recent studies have raised doubts about the efficacy of some common treatments for cardiovascular disease, including: the use of PFO closures (based on the CLOSURE trial); some methods of cardiac resynchronization therapy (or CRT, based on the SMART-AV trial); telemonitoring for patients with congestive heart failure (based on the Tele-HF trial); and doubling the dose of clopidogrel in patients who had a poor response to the drug after percutaneous coronary intervention (based on the GRAVITAS trial). Dr. Robert Harrington, director of the Duke Clinical Research Institute at Duke University Medical Center in Durham, North Carolina, reviews the evidence in each of these trials, and gauges the clinical impact of their findings. Dr. Janet Wright hosts. Produced in Cooperation with

Host: Janet Wright, MD Guest: Robert Harrington, MD Recent studies have raised doubts about the efficacy of some common treatments for cardiovascular disease, including: the use of PFO closures (based on the CLOSURE trial); some methods of cardiac resynchronization therapy (or CRT, based on the SMART-AV trial); telemonitoring for patients with congestive heart failure (based on the Tele-HF trial); and doubling the dose of clopidogrel in patients who had a poor response to the drug after percutaneous coronary intervention (based on the GRAVITAS trial). Dr. Robert Harrington, director of the Duke Clinical Research Institute at Duke University Medical Center in Durham, North Carolina, reviews the evidence in each of these trials, and gauges the clinical impact of their findings. Dr. Janet Wright hosts. <h2>Produced in Cooperation with</h2>

When More Isn't Better: Questioning the Efficacy of Common Cardiovascular Treatments


Host: Jack Lewin, MD     Guest: Stephen Ubl  How do physicians play a particularly crucial role in the development of medical devices, and how does the device innovation model differ from the drug development model? How can we encourage transparent, ethical relationships between healthcare professionals and the medical device industry, as collaborations between these parties are vital to the development process? Mr. Stephen Ubl, president and CEO of AdvaMed, the Advanced Medical Technology Association, provides an overview of the medical device industry landscape, and stresses the need to reward innovation in order to create the environment for new technologies to thrive. Dr. Jack Lewin hosts. 

Host: Jack Lewin, MD Guest: Stephen Ubl How do physicians play a particularly crucial role in the development of medical devices, and how does the device innovation model differ from the drug development model? How can we encourage transparent, ethical relationships between healthcare professionals and the medical device industry, as collaborations between these parties are vital to the development process? Mr. Stephen Ubl, president and CEO of AdvaMed, the Advanced Medical Technology Association, provides an overview of the medical device industry landscape, and stresses the need to reward innovation in order to create the environment for new technologies to thrive. Dr. Jack Lewin hosts.

The Future of Medical Device Innovation


Host: Janet Wright, MD     Guest: Eduardo Marbán, MD, PhD  Stem cell therapies across multiple disciplines continue to demonstrate promising results. How successful are autologous cardiac stem cell treatments proving to be at regenerating cardiac tissue after a heart attack? Which patients would be the best candidates for this procedure, and when might this treatment move from clinical trials into the clinic? Dr. Eduardo Marbán, director of the Cedars-Sinai Heart Institute, developed this procedure, and joins host Dr. Janet Wright to discuss its exciting applications.

Host: Janet Wright, MD Guest: Eduardo Marbán, MD, PhD Stem cell therapies across multiple disciplines continue to demonstrate promising results. How successful are autologous cardiac stem cell treatments proving to be at regenerating cardiac tissue after a heart attack? Which patients would be the best candidates for this procedure, and when might this treatment move from clinical trials into the clinic? Dr. Eduardo Marbán, director of the Cedars-Sinai Heart Institute, developed this procedure, and joins host Dr. Janet Wright to discuss its exciting applications.

Can Autologous Stem Cells Reverse the Damage of a Heart Attack?


Host: Janet Wright, MD     Guest: David Kaplan, PhD  Although most bypass grafts are sourced from other parts of a patient's body, bioengineers are examining new materials that might be used for bypass grafts to reduce the risk of second-site complications. Silk has been a standard material in sutures for decades, and is now showing promise as a biomaterial in bypass grafts. Might silkworms help repair clogged arteries? Dr. David Kaplan, endowed chair, the Stern Family Professor of Engineering, and professor &amp; chair of the department of biomedical engineering at Tufts University, discusses the advantages of silk protein as a biomaterial and related applications to cardiology. When might this new technology be applied from the bench to the bedside? Dr. Janet Wright hosts.    Produced in Cooperation with

Host: Janet Wright, MD Guest: David Kaplan, PhD Although most bypass grafts are sourced from other parts of a patient's body, bioengineers are examining new materials that might be used for bypass grafts to reduce the risk of second-site complications. Silk has been a standard material in sutures for decades, and is now showing promise as a biomaterial in bypass grafts. Might silkworms help repair clogged arteries? Dr. David Kaplan, endowed chair, the Stern Family Professor of Engineering, and professor &amp; chair of the department of biomedical engineering at Tufts University, discusses the advantages of silk protein as a biomaterial and related applications to cardiology. When might this new technology be applied from the bench to the bedside? Dr. Janet Wright hosts. <h2>Produced in Cooperation with</h2>

Could Silkworms Help Repair Clogged Arteries?


Host: Jack Lewin, MD     Guest: John Tooker, MD, MBA, FACP  How can cardiologists and our internal medicine colleagues work together to promote the patient-centered medical home as an efficient strategy for re-organizing care that will reduce costs and improve quality of care? How can we improve communication between specialist and subspecialist providers? Dr. John Tooker, executive vice president and CEO of the American College of Physicians, joins host Dr. Jack Lewin to outline some of the best practices and lessons learned from current integrated health systems, and emphasizes the importance of accountable care organizations. Can some of these lessons even apply to more fragmented delivery of care models?

Host: Jack Lewin, MD Guest: John Tooker, MD, MBA, FACP How can cardiologists and our internal medicine colleagues work together to promote the patient-centered medical home as an efficient strategy for re-organizing care that will reduce costs and improve quality of care? How can we improve communication between specialist and subspecialist providers? Dr. John Tooker, executive vice president and CEO of the American College of Physicians, joins host Dr. Jack Lewin to outline some of the best practices and lessons learned from current integrated health systems, and emphasizes the importance of accountable care organizations. Can some of these lessons even apply to more fragmented delivery of care models?

The Patient-Centered Medical Home: New Delivery Models and Healthcare Reform


Guest: Kevin Weiss, MD     Host: Jack Lewin, MD  Although the Maintenance of Certification (MOC) program may conjure up unpleasant testing jitters, its value to both patients and the medical professional community should not be underestimated. How does MOC improve clinical performance, increase physician accountability and ultimately improve quality of care for patients? How will the MOC program evolve in the future? Dr. Kevin Weiss, president and CEO of the American Board of Medical Specialties, joins host Dr. Jack Lewin to discuss the MOC program's areas of competency as well as plans to integrate MOC with health information technology.  Produced in Cooperation with

Guest: Kevin Weiss, MD Host: Jack Lewin, MD Although the Maintenance of Certification (MOC) program may conjure up unpleasant testing jitters, its value to both patients and the medical professional community should not be underestimated. How does MOC improve clinical performance, increase physician accountability and ultimately improve quality of care for patients? How will the MOC program evolve in the future? Dr. Kevin Weiss, president and CEO of the American Board of Medical Specialties, joins host Dr. Jack Lewin to discuss the MOC program's areas of competency as well as plans to integrate MOC with health information technology.  <h2>Produced in Cooperation with</h2>

The Value and Future of the Maintenance of Certification Program


Host: Jack Lewin, MD     Guest: Ralph Brindis, MD, MPH  How will the recently-passed health reform legislation impact cardiologists and other physicians in the next year? What can physicians do to prepare for the changes ahead? Dr. Ralph Brindis, senior advisor for cardiovascular disease for Northern California Kaiser Permanente, clinical professor of medicine at the University of California, San Francisco, and president of the American College of Cardiology, joins host Dr. Jack Lewin to discuss various elements of health reform, including the further needs for tort reform as well as the sustainable growth rate formula (or SGR) and the need for payment reform. Dr. Brindis also weighs in on the role of registries in measuring success, ensuring quality of care, reducing disparities and decreasing healthcare costs.

Host: Jack Lewin, MD Guest: Ralph Brindis, MD, MPH How will the recently-passed health reform legislation impact cardiologists and other physicians in the next year? What can physicians do to prepare for the changes ahead? Dr. Ralph Brindis, senior advisor for cardiovascular disease for Northern California Kaiser Permanente, clinical professor of medicine at the University of California, San Francisco, and president of the American College of Cardiology, joins host Dr. Jack Lewin to discuss various elements of health reform, including the further needs for tort reform as well as the sustainable growth rate formula (or SGR) and the need for payment reform. Dr. Brindis also weighs in on the role of registries in measuring success, ensuring quality of care, reducing disparities and decreasing healthcare costs.

Health Reform and Cardiology in the Year Ahead


Host: Jack Lewin, MD     Guest: David Blumenthal, MD, MPP  Electronic management of health information will someday replace the pen and paper chart. How significant a role will health information technology, or HIT, play in the newly-reformed healthcare system? What incentives are the federal government offering to foster the widespread, meaningful use of or HIT, and more importantly, what qualifies as meaningful use? Dr. David Blumenthal, National Coordinator for Health Information Technology under President Barack Obama, weighs in on the value of the National Cardiovascular Data Registry and explains meaningful use criteria. How can your practice implement an electronic system that will comply with federal meaningful use guidelines? Hosted by Dr. Jack Lewin.

Host: Jack Lewin, MD Guest: David Blumenthal, MD, MPP Electronic management of health information will someday replace the pen and paper chart. How significant a role will health information technology, or HIT, play in the newly-reformed healthcare system? What incentives are the federal government offering to foster the widespread, meaningful use of or HIT, and more importantly, what qualifies as meaningful use? Dr. David Blumenthal, National Coordinator for Health Information Technology under President Barack Obama, weighs in on the value of the National Cardiovascular Data Registry and explains meaningful use criteria. How can your practice implement an electronic system that will comply with federal meaningful use guidelines? Hosted by Dr. Jack Lewin.

Deciphering Meaningful Use of Health Information Technology


Host: Janet Wright, MD     Guest: Sidney Smith Jr., MD  New evidence strengthens the link between air pollution and heart disease. How strong is the data suggesting a causal relationship between the two? Dr. Sidney Smith, professor of medicine and director of the Center for Cardiovascular Science and Medicine at the University of North Carolina in Chapel Hill says there are two areas of interest in determining the effect of air pollution on the heart. One area being examined is whether air pollution can trigger acute cardiac events, and the other is whether chronic exposure to air pollution can cause the development of long-term cardiovascular disease. Which patients are most at risk for developing cardiovascular health problems from exposure to particulate matter, and how can patients limit their risk of adverse cardiovascular disease-related events from air pollution, even in urban areas? How does heavy air pollution in developing countries or during exercise impact the heart? Dr. Janet Wright hosts.  Produced in Cooperation with

Host: Janet Wright, MD Guest: Sidney Smith Jr., MD New evidence strengthens the link between air pollution and heart disease. How strong is the data suggesting a causal relationship between the two? Dr. Sidney Smith, professor of medicine and director of the Center for Cardiovascular Science and Medicine at the University of North Carolina in Chapel Hill says there are two areas of interest in determining the effect of air pollution on the heart. One area being examined is whether air pollution can trigger acute cardiac events, and the other is whether chronic exposure to air pollution can cause the development of long-term cardiovascular disease. Which patients are most at risk for developing cardiovascular health problems from exposure to particulate matter, and how can patients limit their risk of adverse cardiovascular disease-related events from air pollution, even in urban areas? How does heavy air pollution in developing countries or during exercise impact the heart? Dr. Janet Wright hosts. <h2>Produced in Cooperation with</h2>

Linking Air Pollution and Heart Disease


Host: Janet Wright, MD     Guest: Paul Heidenreich  Sudden cardiac death among high school or college athletes is rare but tragic, and is jarring to families, friends and communities. What additional measures can physicians take to prevent sudden cardiac death among these students? Current guidelines for screening of young athletes in the U.S. do not include electrocardiography but should they, especially in light of recent Italian research about the efficacy of EKG screenings in preventing sudden cardiac death in this population? Dr. Paul Heidenreich, associate professor of medicine (cardiovascular) and associate professor by courtesy of health research and policy, at the Veterens Affairs (VA) Palo Alto Health Care System, and fellow of the Center for Health Policy and the Center for Primary Care and Outcomes Research at Stanford University, weighs the benefits and risks of widespread use of ECG's in the screening of young athletes. Is there a reasonable cost effectiveness value to adding ECG to routine screening for these patients, compared to a routine medical history and physical exam? How should physicians discuss the value of ECG screening with young adult athletes and their parents? Hosted by Dr. Janet Wright. Produced in Cooperation with

Host: Janet Wright, MD Guest: Paul Heidenreich Sudden cardiac death among high school or college athletes is rare but tragic, and is jarring to families, friends and communities. What additional measures can physicians take to prevent sudden cardiac death among these students? Current guidelines for screening of young athletes in the U.S. do not include electrocardiography but should they, especially in light of recent Italian research about the efficacy of EKG screenings in preventing sudden cardiac death in this population? Dr. Paul Heidenreich, associate professor of medicine (cardiovascular) and associate professor by courtesy of health research and policy, at the Veterens Affairs (VA) Palo Alto Health Care System, and fellow of the Center for Health Policy and the Center for Primary Care and Outcomes Research at Stanford University, weighs the benefits and risks of widespread use of ECG's in the screening of young athletes. Is there a reasonable cost effectiveness value to adding ECG to routine screening for these patients, compared to a routine medical history and physical exam? How should physicians discuss the value of ECG screening with young adult athletes and their parents? Hosted by Dr. Janet Wright. <h2>Produced in Cooperation with</h2>

Should We Add ECG to Routine Screening of Young Athletes?


Host: Alfred Bove, MD     Guest: Gregg Stone, MD  Results of a recent study may change the standard of care for patients with acute coronary syndromes. Although clopidogrel is generally the antiplatelet therapy of choice for patients for whom an invasive strategy is planned for treating their acute coronary syndromes, bleeding can be of concern. Prasugrel often presents the same dilemma. Enter, ticagrelor. The PLATelet inhibition and patient Outcomes, or PLATO, trial compared ticagrelor and clopidogrel, which demonstrated promising results for ticagrelor. Dr. Gregg Stone, professor of medicine and director of research and education at the Center for Interventional Vascular Therapy at the Columbia University Medical Center, and director of medical research and education at the Cardiovascular Research Foundation in New York City, hails the PLATO findings as transformative to the standard of care for acute coronary syndromes. He joins host Dr. Alfred Bove to discuss the new place of ticagrelor among the antiplatelet therapy options.

Host: Alfred Bove, MD Guest: Gregg Stone, MD Results of a recent study may change the standard of care for patients with acute coronary syndromes. Although clopidogrel is generally the antiplatelet therapy of choice for patients for whom an invasive strategy is planned for treating their acute coronary syndromes, bleeding can be of concern. Prasugrel often presents the same dilemma. Enter, ticagrelor. The PLATelet inhibition and patient Outcomes, or PLATO, trial compared ticagrelor and clopidogrel, which demonstrated promising results for ticagrelor. Dr. Gregg Stone, professor of medicine and director of research and education at the Center for Interventional Vascular Therapy at the Columbia University Medical Center, and director of medical research and education at the Cardiovascular Research Foundation in New York City, hails the PLATO findings as transformative to the standard of care for acute coronary syndromes. He joins host Dr. Alfred Bove to discuss the new place of ticagrelor among the antiplatelet therapy options.

Transforming the Standard of Care for Acute Coronary Syndromes


Host: Janet Wright, MD     Guest: Mikhail Kosiborod, MD  Elevated blood sugar levels are quite common among even non-diabetic patients presenting with acute myocardial infarction (or AMI). Does lowering a patient's glucose level actually improve outcomes, and if so, what glucose-control therapies are most effective for these patients? Dr. Mikhail Kosiborod, associate professor of medicine at the University of Missouri-Kansas City and cardiologist at St. Luke's Hospital Mid America Heart Institute in Kansas City, Missouri, reviews recent findings about glucose control and AMI with host Dr. Janet Wright. 

Host: Janet Wright, MD Guest: Mikhail Kosiborod, MD Elevated blood sugar levels are quite common among even non-diabetic patients presenting with acute myocardial infarction (or AMI). Does lowering a patient's glucose level actually improve outcomes, and if so, what glucose-control therapies are most effective for these patients? Dr. Mikhail Kosiborod, associate professor of medicine at the University of Missouri-Kansas City and cardiologist at St. Luke's Hospital Mid America Heart Institute in Kansas City, Missouri, reviews recent findings about glucose control and AMI with host Dr. Janet Wright.

Glucose Control After Acute Myocardial Infarction


Host: Jack Lewin, MD     Guest: Rashi Fein, PhD  What can we learn from the past century of healthcare policy that can better inform how we develop such policies today? How has the landscape of medicine and economics surrounding health policy changed, and how have these changes influenced health policy? Join host Dr. Jack Lewin as he welcomes guest Dr. Rashi Fein, professor of the economics of medicine emeritus in the department of global health and social medicine at Harvard Medical School in Boston, and author of the book, Learning Lessons: Medicine, Economics and Public Policy. Although the Affordable Care Act is thousands of pages in length, Dr. Fein suggests that policy makers "keep it simple," even with the most complex health policy issues, in order to have an efficient system that is easy to implement. How can such complicated health policy issues be clearly explained?  Produced in Cooperation with

Host: Jack Lewin, MD Guest: Rashi Fein, PhD What can we learn from the past century of healthcare policy that can better inform how we develop such policies today? How has the landscape of medicine and economics surrounding health policy changed, and how have these changes influenced health policy? Join host Dr. Jack Lewin as he welcomes guest Dr. Rashi Fein, professor of the economics of medicine emeritus in the department of global health and social medicine at Harvard Medical School in Boston, and author of the book, Learning Lessons: Medicine, Economics and Public Policy. Although the Affordable Care Act is thousands of pages in length, Dr. Fein suggests that policy makers "keep it simple," even with the most complex health policy issues, in order to have an efficient system that is easy to implement. How can such complicated health policy issues be clearly explained? Produced in Cooperation with

How to Develop Interdisciplinary, Realistic Health Policies in an Era of Health System Reform


Host: Jack Lewin, MD     Guest: Harry Greenspun, MD  Will healthcare reform do enough to alleviate the current problems in our system, or is the entire delivery model in need of a substantial re-design? Dr. Harry Greenspun, chief medical officer of Dell Services and co-author of the book Reengineering Health Care: A Manifesto for Radically Rethinking Health Care Delivery, says that while health care reform has changed payment models, reform has not done enough to change the delivery system. What elements of our current system are most in need of re-engineering, and how have some organizations successfully transformed their delivery models? Dr. Jack Lewin hosts.    Produced in Cooperation with

Host: Jack Lewin, MD Guest: Harry Greenspun, MD Will healthcare reform do enough to alleviate the current problems in our system, or is the entire delivery model in need of a substantial re-design? Dr. Harry Greenspun, chief medical officer of Dell Services and co-author of the book Reengineering Health Care: A Manifesto for Radically Rethinking Health Care Delivery, says that while health care reform has changed payment models, reform has not done enough to change the delivery system. What elements of our current system are most in need of re-engineering, and how have some organizations successfully transformed their delivery models? Dr. Jack Lewin hosts. <h2>Produced in Cooperation with</h2>

Does the Entire Healthcare System Need a Redesign?


Host: Janet Wright, MD     Guest: Caldwell Esselstyn, Jr., MD  Some evidence suggests it is possible to prevent and reverse heart disease by adhering to a plant-based diet, but lifestyle changes are often the most challenging for physicians to prescribe and for patients to adopt. What strategies can physicians use to encourage a plant-based diet for patients who have or are at risk for having heart disease? Dr. Caldwell Esselstyn, director of the cardiovascular prevention and reversal program at the Cleveland Clinic Wellness Institute in Lyndhurst, Ohio and author of the book, Prevent and Reverse Heart Disease, surveys the worst culprits of the Western diet responsible for causing heart disease, and describes the crucial role that nitric oxide released from the endothelium plays in protecting blood vessels. Dr. Esselstyn shares his tips and strategies for promoting and, most importantly, following a plant-based diet, in the midst of a culture riddled with nutritionally-questionable foods. Join us for part 2 of our two-part interview with Dr. Esselstyn. Dr. Janet Wright hosts. If you missed Part 1, listen now &gt;&gt; Produced in Cooperation with

Host: Janet Wright, MD Guest: Caldwell Esselstyn, Jr., MD Some evidence suggests it is possible to prevent and reverse heart disease by adhering to a plant-based diet, but lifestyle changes are often the most challenging for physicians to prescribe and for patients to adopt. What strategies can physicians use to encourage a plant-based diet for patients who have or are at risk for having heart disease? Dr. Caldwell Esselstyn, director of the cardiovascular prevention and reversal program at the Cleveland Clinic Wellness Institute in Lyndhurst, Ohio and author of the book, Prevent and Reverse Heart Disease, surveys the worst culprits of the Western diet responsible for causing heart disease, and describes the crucial role that nitric oxide released from the endothelium plays in protecting blood vessels. Dr. Esselstyn shares his tips and strategies for promoting and, most importantly, following a plant-based diet, in the midst of a culture riddled with nutritionally-questionable foods. Join us for part 2 of our two-part interview with Dr. Esselstyn. Dr. Janet Wright hosts. If you missed Part 1, <a href="/programs/heart-matters/part-1-a-plant-based-diet-for-preventing-and-possibly-reversing-coronary-artery-disease/6249/" rel="nofollow" target="_blank">listen now &gt;&gt;</a> <h2>Produced in Cooperation with</h2>

Part 2: A Plant-Based Diet for Preventing and Possibly Reversing Coronary Artery Disease


Host: Janet Wright, MD     Guest: Peter Nagele, MD  Time is of the essence after cardiac arrest; action must be taken within five minutes. Survival rates for patients who arrest outside the hospital are disappointing. How do we help patients who arrest in public or (statistically more likely) in the home, where there is no access to medical equipment and medication? Host Dr. Janet Wright talks with Dr. Peter Nagele, chief of the section of trauma anesthesiology in the department of anesthesiology at Washington University in St. Louis, about revised CPR methods without mouth-to-mouth, and what recent research tells us about the potential for these methods to improve outcomes. And what are plans for training the general public?

Host: Janet Wright, MD Guest: Peter Nagele, MD Time is of the essence after cardiac arrest; action must be taken within five minutes. Survival rates for patients who arrest outside the hospital are disappointing. How do we help patients who arrest in public or (statistically more likely) in the home, where there is no access to medical equipment and medication? Host Dr. Janet Wright talks with Dr. Peter Nagele, chief of the section of trauma anesthesiology in the department of anesthesiology at Washington University in St. Louis, about revised CPR methods without mouth-to-mouth, and what recent research tells us about the potential for these methods to improve outcomes. And what are plans for training the general public?

Revising CPR to Improve Cardiac Arrest Outcomes Outside the Hospital


Host: Janet Wright, MD     Guest: Gary Mintz, MD  Acute coronary syndromes in patients who have undergone percutaneous coronary intervention is the subject of the conversation between guest Dr. Gary Mintz, chief medical officer of the Cardiovascular Research Foundation, an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education, and host Dr. Janet Wright. How often do patients who have an acute coronary syndrome have a recurrent event? Their discussion includes protocols, paramaters and outcomes of the PROSPECT trial. The use of ultrasound as well as angiography are also discussed in context to help identify unstable coronary plaques in order to prevent adverse coronary events.

Host: Janet Wright, MD Guest: Gary Mintz, MD Acute coronary syndromes in patients who have undergone percutaneous coronary intervention is the subject of the conversation between guest Dr. Gary Mintz, chief medical officer of the Cardiovascular Research Foundation, an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education, and host Dr. Janet Wright. How often do patients who have an acute coronary syndrome have a recurrent event? Their discussion includes protocols, paramaters and outcomes of the PROSPECT trial. The use of ultrasound as well as angiography are also discussed in context to help identify unstable coronary plaques in order to prevent adverse coronary events.

Identifying Unstable Coronary Plaques


The best podcasts about ourselves as well as the world through the lense of Science. Specific topics include things about our brain, emotions to biology, physics and more!

Best Episodes on Science, Humans & The World

The best podcasts on investing. For anyone interested in the stories in the investing industry, whether it's an interview with Ray Dalio or Ed Thorp to the writer of The Big Short. This topic includes the most fascinating stories from all the best investors. Add episodes you're interested into your queue below!